Search
RARE · Company research

Ultragenyx Pharmaceutical Inc. (RARE): Stock News & Events

Recent company-linked news records available in the database.

Main stock researchCompare stocks
RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

33records availableHealthcare

Stock News & Events data

Database-backed records only

33 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
CFO sells 7,066 Ultragenyx (RARE) shares to pay taxes tied to vesting stock grants. - Stock TitanCFO sells 7,066 Ultragenyx (RARE) shares to pay taxes tied to vesting stock grants. Stock TitanView source ↗Stock TitanOct 19, 2026neutral00.6
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Moved Up to "Hold" by UBS Group - MarketBeatUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Moved Up to "Hold" by UBS Group MarketBeatView source ↗MarketBeatOct 17, 2026neutral00.6
MP Materials vs. USA Rare Earth: Which Rare Earth Stock Is the Better Buy? - The Motley FoolMP Materials vs. USA Rare Earth: Which Rare Earth Stock Is the Better Buy? The Motley FoolView source ↗The Motley FoolOct 17, 2026neutral00.6
MP Materials vs. USA Rare Earth: Which Rare Earth Stock Is the Better Buy? - Yahoo FinanceMP Materials vs. USA Rare Earth: Which Rare Earth Stock Is the Better Buy? Yahoo FinanceView source ↗Yahoo FinanceOct 17, 2026neutral00.6
FOXA Stock Just Scored a Rare Double-Upgrade. Here's Why. - Barchart.comFOXA Stock Just Scored a Rare Double-Upgrade. Here's Why. Barchart.comView source ↗Barchart.comOct 16, 2026neutral00.6
Indonesia faces rare MSCI exclusion that could cut it off from global capital - ReutersIndonesia faces rare MSCI exclusion that could cut it off from global capital ReutersView source ↗ReutersOct 16, 2026neutral00.6
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekUltragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals.View source ↗Zacks Investment ResearchOct 15, 2026bullish0.251
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekUltragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals.View source ↗Zacks Investment ResearchOct 15, 2026bullish0.251
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Yahoo FinanceRARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week Yahoo FinanceView source ↗Yahoo FinanceOct 15, 2026neutral00.6
USA Rare Earth (USAR) Stock May Be Below Fair Value After Funding Deal - Simply Wall StreetUSA Rare Earth (USAR) Stock May Be Below Fair Value After Funding Deal Simply Wall StreetView source ↗Simply Wall StreetOct 14, 2026neutral00.6
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?Ultragenyx Pharmaceutical reported $350 million in first-half 2026 revenues, up 14% year-over-year, driven by Crysvita ($249M) and strong growth in Evkeeza (up 56%). The company received FDA approvals for two new gene therapies—Genglycos and Fayuvi—and sold a priority review voucher for $210 million. However, RARE stock has underperformed, declining 35.1% year-to-date, and faces competition from Amgen and Denali Therapeutics. The company carries a Zacks Rank #3 (Hold) rating.View source ↗Zacks Investment ResearchOct 14, 2026bullish0.3331
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?Ultragenyx Pharmaceutical reported $350 million in first-half 2026 revenues, up 14% year-over-year, driven by Crysvita ($249M) and strong growth in Evkeeza (up 56%). The company received FDA approvals for two new gene therapies—Genglycos and Fayuvi—and sold a priority review voucher for $210 million. However, RARE stock has underperformed, declining 35.1% year-to-date, and faces competition from Amgen and Denali Therapeutics. The company carries a Zacks Rank #3 (Hold) rating.View source ↗Zacks Investment ResearchOct 14, 2026bullish0.3331
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - TradingViewCan RARE's Approved Product Portfolio Drive Its Next Growth Phase? TradingViewView source ↗TradingViewOct 14, 2026neutral00.6
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr. - MarketBeatUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr. MarketBeatView source ↗MarketBeatOct 14, 2026neutral00.6
How This Rare Options Strategy Might Work On AMD Stock - Investor's Business DailyHow This Rare Options Strategy Might Work On AMD Stock Investor's Business DailyView source ↗Investor's Business DailyOct 13, 2026neutral00.6
For the Second Time in History, the Stock Market Sends a Rare Warning Signal and Points to Looming Trouble Ahead - The Motley FoolFor the Second Time in History, the Stock Market Sends a Rare Warning Signal and Points to Looming Trouble Ahead The Motley FoolView source ↗The Motley FoolOct 13, 2026neutral00.6
USA Rare Earth Drops 6% With Milestone-Based Government Funding Still Ahead of It; MP Materials Falls 6%, Critical Metals Holds Steady - Yahoo FinanceUSA Rare Earth Drops 6% With Milestone-Based Government Funding Still Ahead of It; MP Materials Falls 6%, Critical Metals Holds Steady Yahoo FinanceView source ↗Yahoo FinanceOct 12, 2026neutral00.6
MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading - StocktwitsMRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading StocktwitsView source ↗StocktwitsOct 12, 2026neutral00.6
USA Rare Earth: The Price Assumes A Western Premium The Contract Doesn't Promise (USAR) - Seeking AlphaUSA Rare Earth: The Price Assumes A Western Premium The Contract Doesn't Promise (USAR) Seeking AlphaView source ↗Seeking AlphaOct 12, 2026neutral00.6
5 Best Rare Earth Stocks To Buy And Invest In 2027 - Forbes5 Best Rare Earth Stocks To Buy And Invest In 2027 ForbesView source ↗ForbesOct 11, 2026neutral00.6
Ultragenyx (RARE) Stock Looks About Right After Voucher Sale - Simply Wall StreetUltragenyx (RARE) Stock Looks About Right After Voucher Sale Simply Wall StreetView source ↗Simply Wall StreetOct 9, 2026neutral00.6
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashUltragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing.View source ↗Zacks Investment ResearchOct 8, 2026bullish0.251
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashUltragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing.View source ↗Zacks Investment ResearchOct 8, 2026bullish0.251
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashUltragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing.View source ↗Zacks Investment ResearchOct 8, 2026bullish0.251
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Yahoo FinanceUltragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash Yahoo FinanceView source ↗Yahoo FinanceOct 8, 2026neutral00.6
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc. - OSISPomerantz LLP announced investigations into potential securities fraud and unlawful business practices at OSI Systems, lululemon athletica, and Ultragenyx Pharmaceutical. The investigation into OSI was triggered by the company's August 20, 2026 earnings report that missed revenue expectations due to deferred product deliveries, resulting in a 5.21% stock price decline.View source ↗GlobeNewswire Inc.Oct 6, 2026bearish-11
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc. - OSISPomerantz LLP announced investigations into potential securities fraud and unlawful business practices at OSI Systems, lululemon athletica, and Ultragenyx Pharmaceutical. The investigation into OSI was triggered by the company's August 20, 2026 earnings report that missed revenue expectations due to deferred product deliveries, resulting in a 5.21% stock price decline.View source ↗GlobeNewswire Inc.Oct 6, 2026bearish-11
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREPomerantz LLP announced investigations into potential securities fraud at Ultragenyx Pharmaceutical, OSI Systems, and lululemon athletica. The investigation into Ultragenyx was triggered by the company's failure to meet primary endpoints in a Phase 3 clinical trial for apazunersen, resulting in a 44% stock price decline on September 3, 2026.View source ↗GlobeNewswire Inc.Oct 6, 2026bearish-11
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREPomerantz LLP announced investigations into potential securities fraud at Ultragenyx Pharmaceutical, OSI Systems, and lululemon athletica. The investigation into Ultragenyx was triggered by the company's failure to meet primary endpoints in a Phase 3 clinical trial for apazunersen, resulting in a 44% stock price decline on September 3, 2026.View source ↗GlobeNewswire Inc.Oct 6, 2026bearish-11
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6% - Here's Why - MarketBeatUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6% - Here's Why MarketBeatView source ↗MarketBeatOct 5, 2026neutral00.6
This rare stock-market divide means an elevated chance of a big surge — or a deep plunge - MarketWatchThis rare stock-market divide means an elevated chance of a big surge — or a deep plunge MarketWatchView source ↗MarketWatchOct 5, 2026neutral00.6
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial - Pharmaceutical ExecutiveUltragenyx Shares Drop Following Failed Phase III Clinical Trial Pharmaceutical ExecutiveView source ↗Pharmaceutical ExecutiveSep 3, 2026neutral00.6
Why Did RARE Stock Slump 46% After-Hours? - StocktwitsWhy Did RARE Stock Slump 46% After-Hours? StocktwitsView source ↗StocktwitsSep 2, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.